sellModerate cluster of 4
INGENITO GARY sold $806k of CPRX
Chief Med. & Reg. Officer at CATALYST PHARMACEUTICALS, INC.. 38,000 shares at an average of $21.20, traded Nov 20, 2024, filed Nov 22, 2024.
Warning score
47Value
$806k
38,000 shares
Holdings after
51,391
-43% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001161697-24-000458, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | MOption exercise Common stock, par value $0.001 per share | +38,000 | $4.01 | $152k | 89,391 | Nov 22, 2024 |
| Nov 20, 2024 | SOpen-market sale Common stock, par value $0.001 per share | -38,000 | $21.20 | $806k | 51,391 | Nov 22, 2024 |
| Nov 20, 2024 | MOption exercise Options to purchase common stockderivative | -38,000 | $0.00 | $0 | 912,575 | Nov 22, 2024 |
Related signals
Other insiders at CATALYST PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 40Moderate | sell 4 | CPRX CATALYST PHARMACEUTICALS, INC. | Miller Steve Chief Op. & Scientific Officer | $1.1M | 50,000 | |
| 29Weak | sell 5 | CPRX CATALYST PHARMACEUTICALS, INC. | Elsbernd Brian Chief Compliance/Legal Officer | $287k | 13,256 | |
| 51Moderate | sell 5 | CPRX CATALYST PHARMACEUTICALS, INC. | Harper Molly director | $385k | 17,500 | |
| 33Weak | sell 5 | CPRX CATALYST PHARMACEUTICALS, INC. | INGENITO GARY Chief Med. & Reg. Officer | $273k | 12,000 | |
| 40Moderate | sell 4 | CPRX CATALYST PHARMACEUTICALS, INC. | MCENANY PATRICK J director, other | $3.6M | 170,845 | |
| 40Moderate | sell 4 | CPRX CATALYST PHARMACEUTICALS, INC. | MCENANY PATRICK J director, other | $3.1M | 137,155 | |
| 38Weak | sell 2 | CPRX CATALYST PHARMACEUTICALS, INC. | MCENANY PATRICK J director, other | $12M | 492,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.